The recent American Diabetes Association / European Association for the Study of Diabetes consensus panel produced their treatment algorithm to control glycaemia in type 2 diabetes. How can healthcare professionals treating patients with type 2 diabetes provide additional prandial intervention to reach A1c targets? Join host Dr. Steven Edelman and his guest, professor of medicine at the University of North Carolina School of Medicine, Dr. John Buse, as they discuss the results of the glargine-exenatide combination study and its implications for a preferred treatment algorithm.
New Treatment Algorithm for Type 2 Diabetes
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
The recent American Diabetes Association / European Association for the Study of Diabetes consensus panel produced their treatment algorithm to control glycaemia in type 2 diabetes. How can healthcare professionals treating patients with type 2 diabetes provide additional prandial intervention to reach A1c targets? Join host Dr. Steven Edelman and his guest, professor of medicine at the University of North Carolina School of Medicine, Dr. John Buse, as they discuss the results of the glargine-exenatide combination study and its implications for a preferred treatment algorithm.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Evolving Our View of the Coagulation Cascade and Stroke Management
0.25 credits
<p><span data-contrast="auto" xml:lang="EN-US">Evolving Our View of the Coagulation Cascade and Stroke Management</span><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p>
MinuteCE®
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
1.00 credits
<p>I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis</p>
MinuteCE®
M3: Managing the Cardiometabolic Risk in MASH
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">M3: Managing the Cardiometabolic Risk in MASH</span><span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'> </span></p>
Perspectives with the AMA
Implementing the AMA MAPTM Hypertension Program: A Clinician’s Experience
<p>Implementing the AMA MAP™ Hypertension Program: A Clinician's Experience</p>
MinuteCE®
The Heart’s Aftermath: IRI’s Impact on Cardiac Morbidity & Mortality
0.50 credits
<p>The Heart’s Aftermath: IRI’s Impact on Cardiac Morbidity & Mortality</p>
MinuteCE®
Biomarkers of the Storm: Decoding IRI’s Signature
0.50 credits
<p>Biomarkers of the Storm: Decoding IRI’s Signature</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
CME/CE
Impact of Barostim on Heart Failure Hospitalization
<p>Impact of Barostim on Heart Failure Hospitalization</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?